Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders

Roehrig, S; Ackerstaff, J; Núñez, EJ; Teller, H; Ellerbrock, P; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Lang, D; Schlemmer, KH; Schaefer, M; Gericke, KM; Kinzel, T; Meibom, D; Schmidt, M; Gerdes, C; Follmann, M; Hillisch, A

Roehrig, S (通讯作者)，Bayer AG, Pharmaceut Res & Dev, D-42133 Wuppertal, Germany.

JOURNAL OF MEDICINAL CHEMISTRY, 2023; 66 (17): 12203

Abstract

Activated coagulation factor XI (FXIa) is a highly attractive antithrombotic target as it contributes to the development and progression of thrombosis......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索